Excellent - I now have the full treatment algorithm image plus comprehensive drug-by-drug and species-by-species content. I have everything needed for a thorough answer.
Treatment of Malaria by Plasmodium Species
Treatment Decision Algorithm
Fig. 66-3 - Decision algorithm for treatment of malaria, Goodman & Gilman's Pharmacological Basis of Therapeutics
Core Principle: Two Questions Drive Drug Choice
- Which species? (determines if you need radical cure for relapsing forms)
- Chloroquine-sensitive or resistant? (the single most important question for P. falciparum)
1. P. vivax and P. ovale (Relapsing Malaria)
These two species form dormant hypnozoites in the liver that cause relapses weeks to months after the initial infection. Treatment therefore has two components:
Blood-stage treatment (eliminates circulating merozoites)
| Acquisition region | Drug |
|---|
| Most areas | Chloroquine 25 mg/kg over 3 days (10 mg/kg day 1, 10 mg/kg day 2, 5 mg/kg day 3) |
| Papua New Guinea / Indonesia (P. vivax chloroquine-resistant) | Atovaquone-proguanil, or quinine + tetracycline/doxycycline, or mefloquine |
Radical cure (eliminates liver hypnozoites - prevents relapse)
| Drug | Dose | Notes |
|---|
| Primaquine | 0.25-0.5 mg/kg/day × 14 days | Supervised; most widely used |
| Tafenoquine | 300 mg single dose | Newer; more convenient |
Critical: Both primaquine and tafenoquine cause hemolysis in G6PD-deficient patients. Test for G6PD deficiency before prescribing. Both are contraindicated in pregnancy and in infants. - Goldman-Cecil Medicine
2. P. malariae
- No hypnozoites; no radical cure needed.
- Treated with chloroquine alone (same schedule as vivax).
- Generally mild and chloroquine-sensitive worldwide.
3. P. knowlesi (Zoonotic, SE Asia)
- More virulent course than P. malariae despite similar appearance.
- Treated with chloroquine or hydroxychloroquine (chloroquine-sensitive).
- If acquired in a chloroquine-resistant region, treat as chloroquine-resistant P. falciparum.
4. P. falciparum - Uncomplicated Disease
If acquired in chloroquine-SENSITIVE area
(Haiti, Dominican Republic, Central America north of Panama Canal, limited Middle East)
Chloroquine phosphate: 1 g → 500 mg at 6 h → 500 mg at 24 h → 500 mg at 48 h
If acquired in chloroquine-RESISTANT area (majority of the world)
Choose one of:
| Regimen | Adult Dose | Notes |
|---|
| Artemether-lumefantrine (Coartem) | 4 tabs twice daily × 3 days | First-line globally; FDA approved; no documented lumefantrine resistance |
| Atovaquone-proguanil (Malarone) | 4 tabs daily × 3 days | Excellent efficacy; well tolerated; expensive |
| Quinine + doxycycline | Quinine 650 mg TID × 3-7 days + doxycycline 100 mg BID × 7 days | Doxycycline not for children <8 years |
| Quinine + clindamycin | Quinine 650 mg TID × 7 days + clindamycin 600 mg BID × 7 days | For children and pregnant women |
| Mefloquine | 750 mg then 500 mg in 6-8 h | Single 1250 mg dose less tolerated; resistance in SE Asia |
If acquired in mefloquine-RESISTANT area (parts of SE Asia)
- Artesunate-mefloquine combination or dihydroartemisinin-piperaquine
- Artesunate-pyronaridine (newer; no documented resistance to either component)
ACT monotherapy is banned - artemisinin must always be used in combination to prevent resistance development. - Park's Preventive & Social Medicine
5. P. falciparum - Severe/Complicated Disease
Severe malaria is defined by: coma, convulsions, severe anemia (Hb <5 g/dL), renal failure (creatinine >3 mg/dL), jaundice (bilirubin >3 mg/dL), pulmonary edema/ARDS, hypoglycemia (glucose <40 mg/dL), hyperparasitemia (>5% RBCs infected), circulatory collapse, DIC, or hemoglobinuria.
Parenteral therapy is mandatory. This is a medical emergency.
| Drug | Dose | Notes |
|---|
| IV Artesunate (first-line) | 2.4 mg/kg at 0, 12, 24 h, then daily | Superior to quinine; fewer side effects; obtain via CDC Malaria Hotline (770-488-7788) in the US |
| IV Quinine dihydrochloride (alternative) | 20 mg/kg loading over 4 h, then 10 mg/kg every 8 h | Requires continuous cardiac monitoring (QT prolongation); not as efficacious as artesunate |
| IM Artemether (alternative) | 3.2 mg/kg IM, then 1.6 mg/kg/day | Not available in the US |
Switch to oral therapy once patient can tolerate it, and complete a full course (doxycycline, clindamycin, or full ACT).
Supportive care for severe malaria:
- Close nursing care and fluid/electrolyte maintenance
- Glucose monitoring and replacement (hypoglycemia is common, worsened by quinine)
- Respiratory support for ARDS
- Anticonvulsants for seizures
- Transfusion only if Hb <5 g/dL (avoid in pulmonary edema)
6. Malaria in Pregnancy
| Trimester | P. falciparum | P. vivax |
|---|
| 1st trimester | Quinine + clindamycin (ACTs avoided) | Chloroquine |
| 2nd & 3rd trimester | ACT (artemether-lumefantrine preferred) | Chloroquine |
- Primaquine and tafenoquine are contraindicated throughout pregnancy.
- Breastfeeding: chloroquine/hydroxychloroquine preferred; check infant G6PD before any primaquine.
7. Mixed Infections
Treat as the most severe species present - mixed infections with P. falciparum are treated with the P. falciparum regimen. Then add primaquine if P. vivax or P. ovale is confirmed, after G6PD testing.
ACT Regimens Used Globally (WHO-Recommended)
| ACT Combination | Where Used |
|---|
| Artemether-lumefantrine (Coartem) | First-line in most countries; FDA approved |
| Artesunate-amodiaquine (ASAQ) | First-line in parts of Africa |
| Artesunate-mefloquine | Standard in SE Asia (resistance emerging) |
| Dihydroartemisinin-piperaquine | Highly effective; resistance in SE Asia |
| Artesunate-pyronaridine | Newer; efficacious; no documented resistance |
A 2025 meta-analysis (
Bohissou et al., BMC Infect Dis, PMID 41291512) confirmed ACT efficacy across sub-Saharan Africa 2010-2024, though with emerging resistance signals in some regions - reinforcing WHO recommendations to monitor treatment response and consider second-line agents where ACT failure is suspected.
Quick Reference by Species
| Species | Radical cure needed? | Blood-stage drug | Anti-relapse drug |
|---|
| P. falciparum | No | ACT or chloroquine (if sensitive) | Primaquine 0.75 mg/kg single dose (reduce transmission only) |
| P. vivax | Yes | Chloroquine (or ACT if resistant) | Primaquine × 14 days or tafenoquine single dose |
| P. ovale | Yes | Chloroquine | Primaquine × 14 days or tafenoquine single dose |
| P. malariae | No | Chloroquine | None needed |
| P. knowlesi | No | Chloroquine | None needed |
Sources:
- Goodman & Gilman's Pharmacological Basis of Therapeutics, Ch. 66
- Goldman-Cecil Medicine (International Ed.), Ch. 316
- Park's Textbook of Preventive & Social Medicine, Ch. on Malaria
- Katzung's Basic & Clinical Pharmacology, 16th Ed., Ch. 52